Neogen said it expects regulatory review of its planned sale of its global Genomics business to Zoetis to conclude in early 2027. The deal, first announced March 2, 2026, remains subject to customary closing conditions and regulatory approvals, and Zoetis has offered to divest certain Australian assets to help clear the review. The filing gives no purchase price or financial impact, so shareholders face a longer timeline before the transaction can close.
Neogen agreed on March 2, 2026 to sell its global Genomics business to Zoetis Inc.
The Australian Competition and Consumer Commission and New Zealand Commerce Commission are continuing reviews of the transaction.
Zoetis has offered to divest certain assets in Australia to assist the clearance process.
Neogen expects regulatory review to conclude in early 2027.
Neogen reported first-quarter fiscal 2027 revenue of $222.8 million, up 6.5% from a year earlier, and raised its fiscal 2027 revenue and Adjusted EBITDA guidance. The company still posted a GAAP net loss of $11.9 million, compared with net income of $36.3 million a year earlier, when a $76.4 million gain on the sale of a business boosted results.
Revenue of $222.8 million vs. $209.2 million a year earlier; core revenue growth of 8.1%
Net loss of $11.9 million, or $(0.05) per diluted share, vs. net income of $36.3 million, or $0.17, a year earlier; Adjusted EPS was $0.08 vs. $0.04
Fiscal 2027 revenue guidance raised to $885 million to $890 million from $880 million to $885 million; Adjusted EBITDA guidance raised to $181 million to $183 million from $180 million to $182 million
Pending sale of the Genomics business to Zoetis Inc. is expected to conclude regulatory reviews by the end of December 2026
Neogen Corporation disclosed that director Thierry Bernard resigned from its Board of Directors on August 3, 2026. The filing does not state a reason for the resignation or name a replacement.
Thierry Bernard resigned from the Neogen Board of Directors on August 3, 2026.
The filing gives no reason for the resignation.
No successor director or board appointment is named in this filing.
Neogen reported fiscal fourth-quarter 2026 revenue of $225.3 million, down 0.1% from a year earlier, with core revenue growth of 4.3%. The net loss narrowed sharply from $612.2 million a year earlier, which included a $597.9 million goodwill impairment, and the company gave fiscal 2027 revenue guidance of $880 million to $885 million and adjusted EBITDA of $180 million to $182 million.
Q4 fiscal 2026 revenue $225.3 million vs $225.5 million a year earlier; full fiscal year revenue $870.4 million, down 2.7%
Q4 net loss $11.3 million, or $(0.05) per diluted share, vs $(2.82) a year earlier; adjusted EPS $0.09 vs $0.05
Q4 adjusted EBITDA $45.4 million, margin 20.2%, vs $40.6 million and 18.0% a year earlier
FY27 guidance: revenue $880 million to $885 million and adjusted EBITDA about $180 million to $182 million, excluding the pending Genomics sale to Zoetis Inc. details to be updated later
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.